97 related articles for article (PubMed ID: 6850552)
1. Crystallographic studies of the antineoplastic antifolate 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) ethanesulfonate salt.
Cody V
Cancer Biochem Biophys; 1983; 6(3):173-7. PubMed ID: 6850552
[TBL] [Abstract][Full Text] [Related]
2. Computer graphic modeling in drug design--conformational analysis of antifolate binding to avian dihydrofolate reductase: crystal and molecular structures of 2,4-diamino-5-cyclohexyl-6-methylpyrimidine and 5-cyclohexyl-6-methyluracil.
Cody V; Ciszak E
Anticancer Drug Des; 1991 May; 6(2):83-93. PubMed ID: 2039584
[TBL] [Abstract][Full Text] [Related]
3. CNDO/2 molecular orbital calculations on the antifolate DAMP and some related species: structural geometries, ring distortions, change distributions and conformational characteristics.
Welsh WJ; Cody V; Mark JE; Zakrzewski SF
Cancer Biochem Biophys; 1983 Dec; 7(1):27-38. PubMed ID: 6667452
[TBL] [Abstract][Full Text] [Related]
4. Molecular structures of 2,4-diaminopyrimidine antifolates with antineoplastic activity.
Cody V; Zakrzewski SF
J Med Chem; 1982 Apr; 25(4):427-30. PubMed ID: 7069721
[TBL] [Abstract][Full Text] [Related]
5. Conformational analysis of lipophilic antifolates: crystal and molecular structures of three s-triazine dihydrofolate reductase inhibitors.
Cody V; Sutton PA
Anticancer Drug Des; 1987 Dec; 2(3):253-62. PubMed ID: 3449089
[TBL] [Abstract][Full Text] [Related]
6. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
[TBL] [Abstract][Full Text] [Related]
7. Human plasma and amino acids as moderators of uptake and metabolic consequences of antifolates in WIL-2 and human leukemia cells.
Fyfe MJ; Sedwick WD; Brown OE; Laszlo J
J Natl Cancer Inst; 1981 Mar; 66(3):445-51. PubMed ID: 6937701
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular hydrogen-bonding patterns in salts of the antifolate drugs trimethoprim and pyrimethamine.
Swinton Darious R; Thomas Muthiah P; Perdih F
Acta Crystallogr C Struct Chem; 2018 Apr; 74(Pt 4):487-503. PubMed ID: 29620034
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
Kalghatgi KK; Moroson BA; Horváth C; Bertino JR
Cancer Res; 1979 Sep; 39(9):3441-5. PubMed ID: 476673
[TBL] [Abstract][Full Text] [Related]
10. Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate.
Browman GP; Gorka C; Mehta C; Lazarus H; Abelson HT
Biochem Pharmacol; 1980 Aug; 29(16):2241-5. PubMed ID: 7426028
[No Abstract] [Full Text] [Related]
11. Structural studies on bio-active compounds. Part 9. 2,4-Diamino-6-azidoquinazoline hydrochloride.
Schwalbe CH; King ME; Wong KP; Lambert PA; Bliss A; Stevens MF
Anticancer Drug Des; 1987 Dec; 2(3):289-96. PubMed ID: 3449092
[TBL] [Abstract][Full Text] [Related]
12. An enzyme inhibition assay for 2,4-diamino-5-(3'4'-dichlorophenyl)-6-methylpyrimidine (DDMP,NSC 19494).
Calvert AH; Cridland JS; Harrap KR
J Clin Pathol; 1977 Dec; 30(12):1154-7. PubMed ID: 604362
[TBL] [Abstract][Full Text] [Related]
13. Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
Nichol CA; Cavallito JC; Woolley JL; Sigel CW
Cancer Treat Rep; 1977 Jul; 61(4):559-64. PubMed ID: 301777
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of diamino-dichlorophenyl-methylpyrimidine (DDMP) with folinic acid (CF) protection and rescue.
Alberto P; Brugarolas A; Hansen HH; Cavalli F; Klepp O; Renard J
Eur J Cancer (1965); 1980 Sep; 16(9):1243-9. PubMed ID: 6971756
[No Abstract] [Full Text] [Related]
15. Phase II clinical trial of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors.
de Jager R; Brugarolas A; Hansen M
Cancer Chemother Pharmacol; 1981; 6(1):81-4. PubMed ID: 6974059
[TBL] [Abstract][Full Text] [Related]
16. Aminopyrimidine-carboxyl(ate) interactions in trimethoprim maleate, an antifolate drug.
Prabakaran P; Robert JJ; Muthiah PT; Bocelli G; Righi L
Acta Crystallogr C; 2001 Apr; 57(Pt 4):459-61. PubMed ID: 11313594
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).
de Jager R; Dupont D; Rodzynek JJ; Dorlet C; Lagrange G
Cancer Chemother Pharmacol; 1981; 6(1):75-80. PubMed ID: 6974058
[TBL] [Abstract][Full Text] [Related]
18. Effect of DDMP (2, 4-diamino-5-3', 4'-dichlorophenyl-6-methylpyrimidine) on brain gliomas--a phase II study. E.O.R.T.C. Brain Tumor Group.
Eur J Cancer (1965); 1980 Dec; 16(12):1639-40. PubMed ID: 7227437
[No Abstract] [Full Text] [Related]
19. DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-methylpyrimidine).
Hill BT; Price LA
Cancer Treat Rev; 1980 Jun; 7(2):95-112. PubMed ID: 6996812
[No Abstract] [Full Text] [Related]
20. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
Cody V; Pace J; Chisum K; Rosowsky A
Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
